Prospective, Open-label, Randomized, Parallel-group, Multicenter, Investigator, Initiated Phase 4 Clinical Trial to Evaluate the Glycemic Lowering Effects of Adding SGLT2 Inhibitor Monotherapy, TZD Monotherapy, or SGLT2 Inhibitor/TZD Combination Therapy in Patients With Type 2 Diabetes on DPP4 Inhibitors

This clinical trial investigates the effects of adding different diabetes medications to patients with type 2 diabetes who are currently being treated with DPP4 inhibitors. The study evaluates three treatment strategies: SGLT2 inhibitor monotherapy, TZD monotherapy, and a combination of both SGLT2 inhibitor and TZD. Participants will be randomly assigned to one of four groups, including a control group continuing DPP4 inhibitor alone.
The primary objective is to assess changes in blood sugar control, specifically HbA1c levels, after 12 and 24 weeks of treatment. Secondary outcomes include changes in fasting and postprandial glucose, insulin, C-peptide, lipid profiles (total cholesterol, triglycerides, HDL-C, LDL-C), body composition (muscle mass, visceral fat, subcutaneous fat), and insulin resistance indicators such as HOMA-IR, HOMA-beta, and Insulinogenic Index.
Eligible participants are adults aged 19 to 75 years with type 2 diabetes who have been on stable doses of DPP4 inhibitors, with or without metformin or sulfonylurea, for at least 8 weeks. Individuals with recent use of SGLT2 inhibitors or TZDs, significant organ dysfunction, or other exclusion criteria will not be enrolled.
The study is open-label and multicenter, conducted at four hospitals in Korea. All medications used in the trial are provided by the sponsor. Participants will receive lifestyle counseling throughout the study period, including guidance on diet and exercise. Safety monitoring will be conducted regularly, and adverse events will be documented and managed according to protocol.

Start Date01 Sep 2025

Sponsor / Collaborator

Yonsei University

NCT07056517

/ RecruitingPhase 1

A Single-Dose, Open-label, Pharmacokinetics Study of Lobeglitazone From M107 ODT and Duvie? Under Fasted and Fed Conditions in Healthy Adults

Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of lobeglitazone administered as M107 Orally Disintegrating Tablet and Duvie tablet in healthy adult participants under fasted and fed conditions.

Start Date11 Jul 2025

Sponsor / Collaborator

Aclipse Two Inc.

NCT05897216

/ CompletedPhase 1

A Randomized, Open-label, Single Oral Dosing, Two-sequence, and Two-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between Administration of CKD-383 and Co-administration of CKD-501, D745, D150, and D029

Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D745, D150 and D029 for Healthy Subjects in Fed State

Start Date14 Jul 2023

Sponsor / Collaborator

Chong Kun Dang Pharmaceutical Corp.

100 Clinical Results associated with Lobeglitazone Sulfate

100 Translational Medicine associated with Lobeglitazone Sulfate

100 Patents (Medical) associated with Lobeglitazone Sulfate

Literatures (Medical) associated with Lobeglitazone Sulfate

01 Jan 2026·DIABETES OBESITY & METABOLISM

Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial

Article

Author: Min, Kyung Wan ; Sohn, Ho Sang ; Kim, Sang Yong ; Kim, So Hun ; Cha, Bong‐Soo ; Park, Cheol‐Young ; Seo, Da Hea ; Yoon, Kun‐Ho ; Jeong, In‐Kyung

Abstract:

Aims:

This study aimed to evaluate the efficacy and safety of triple therapy with lobeglitazone 0.5 mg as an add‐on treatment compared with placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin.

Materials and Methods:

In this Phase 3, multicentre, double‐blind, randomised trial, patients with T2DM who had an insufficient response to metformin (≥1000 mg/day) and empagliflozin 10 mg/day (Study 1) or 25 mg/day (Study 2) were randomised to receive either lobeglitazone 0.5 mg/day, or placebo once daily for 24 weeks. Participants then entered an open‐label extension phase for an additional 28 weeks, bringing the total treatment duration to 52 weeks. The primary endpoint was the change from baseline in glycated haemoglobin ( HbA1c ) at 24 weeks.

Results:

At 24 weeks, the mean change in HbA1c was significantly greater with lobeglitazone than with placebo, regardless of the background empagliflozin dose (−0.71%; 95% confidence interval, −0.88 to −0.55; p < 0.001 in Study 1 and −0.62%; −0.79 to −0.45; p < 0.001 in Study 2). A higher proportion of patients achieved HbA1c levels <7% with lobeglitazone compared to placebo (48.7% vs. 13.4% in Study 1, and 44.4% vs. 13.0% in Study 2; p < 0.001). Although the incidence of adverse events was numerically different between groups, no statistically significant differences were observed, indicating a generally comparable profile for the triple combination therapy with metformin, empagliflozin, and lobeglitazone.

Conclusions:

Lobeglitazone as an add‐on to empagliflozin and metformin significantly improved glycaemic control in patients with T2DM inadequately controlled on metformin and empagliflozin dual therapy. The treatment was well tolerated, with a low incidence of adverse events.

01 Jan 2026·BIOMEDICAL CHROMATOGRAPHY

From Separation to Safety Prediction: Validated RP‐HPLC Method for Simultaneous Estimation of Sitagliptin and Lobeglitazone, LC‐MS/MS Identification of Degradant Products, and In Silico Safety Profiling

Article

Author: Patel, Rutvi ; Prajapati, Viraj ; Shah, Kushal ; Thummar, Kashyap ; Panchal, Gaurav ; Moradia, Akshita

ABSTRACT:

Diabetes mellitus is a global health burden, necessitating effective combination therapies. The fixed‐dose formulation of sitagliptin phosphate (SGP, 100 mg) and lobeglitazone sulfate (LGS, 0.5 mg) offers synergistic benefits by enhancing insulin sensitivity and glucose‐dependent insulin secretion. However, simultaneous quantification remains challenging due to their dosage disparity and the narrow therapeutic index of LGS. This study reports a validated, stability‐indicating RP‐HPLC method for concurrent estimation of SGP and LGS in a synthetic mixture. Separation was achieved on a Pursuit 5 Diphenyl column (150 × 4.6 mm, 5 μm) using a gradient of 0.1% formic acid and acetonitrile at 1.0 mL/min, with PDA detection at 254 nm. The method complied with ICH Q2(R2) guidelines, showing specificity, linearity, accuracy, precision, and robustness. Forced degradation studies revealed marked instability of SGP under acidic and alkaline conditions, whereas LGS remained stable. LC‐MS/MS analysis identified a major degradation product at m / z 234, and probable fragmentation pathways were proposed. In silico ADMET and toxicity profiling predicted high gastrointestinal absorption for all degradation products, with PI‐1 and PI‐2 flagged for carcinogenicity and all except PI‐3 showing nephrotoxicity. This integrated analytical–computational approach provides a reliable tool for quality control and safety assessment of this antidiabetic formulation.

01 Oct 2025·DIABETES OBESITY & METABOLISM

Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52‐week, multicentre, randomized, placebo‐controlled, phase III clinical trial

Article

Author: Sungrae Kim MD ; Dong-Jun Kim MD ; Seungjoon Oh MD ; Tae Seo Sohn MD ; Chang Beom Lee MD ; Hye Soon Kim MD ; Sang Soo Kim MD ; Kyung-Wan Min MD ; SungWan Chun MD ; Young Min Cho MD ; Ji Oh Mok MD ; Jeong Hyun Park MD ; Kyu Yeon Hur MD ; Chong Hwa Kim MD ; Kun-Ho Yoon MD ; Byung-Joon Kim MD ; Eun-Gyoung Hong MD ; Sung Hee Choi MD ; Choon Hee Chung MD

Abstract:

Aims:

To evaluate the efficacy and safety of adding lobeglitazone to a triple therapy regimen in Korean patients with type 2 diabetes whose blood glucose levels were inadequately controlled despite dual therapy with metformin and sitagliptin.

Materials and Methods:

This randomised, double‐blind, placebo‐controlled, phase 3 study involved 231 Korean patients with type 2 diabetes whose HbA1c levels ranged from 7.0% to 10.0% despite treatment with metformin (≥1000 mg/day) and sitagliptin (100 mg/day). Participants received lobeglitazone (0.5 mg/day) or placebo for 24 weeks, followed by a 28‐week open‐label phase in which all patients received lobeglitazone. The primary endpoint was the change in glycated haemoglobin (HbA1c) at 24 weeks; secondary endpoints included changes in fasting plasma glucose (FPG), homeostatic model assessment for insulin resistance (HOMA‐IR), HOMA for β‐cell function (HOMA‐β), quantitative insulin‐sensitivity check index (QUICKI) and lipid profile. Safety assessments were also conducted.

Results:

At week 24, lobeglitazone treatment demonstrated a significantly greater reduction in HbA1c compared with placebo (−1.00% ± 0.09% vs. 0.02% ± 0.09%), with a between‐group difference in the adjusted mean change [−1.03%; p < 0.0001]. Additionally, lobeglitazone significantly reduced FPG compared with placebo at week 24 and improved HOMA‐IR, HOMA‐β and QUICKI. Lipid parameters were also improved by lobeglitazone administration. Adverse events were similar in both treatment arms.

Conclusions:

The addition of lobeglitazone in patients with type 2 diabetes inadequately controlled with metformin and sitagliptin is a beneficial therapeutic option, not only providing effective glycaemic control but also improving insulin function such as sensitivity and enhancing certain lipid parameters.

News (Medical) associated with Lobeglitazone Sulfate

17 Nov 2025

·www.businesswire.com

Aclipse Therapeutics to Collaborate with Mayo Clinic on Phase 2 Clinical Development of M107 for the Treatment of Gastroparesis

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Aclipse Therapeutics LLC (“Aclipse” or “the Company”) today announced that it has entered into a clinical collaboration and Know-How Agreement with Mayo Clinic for the Phase 2 clinical development of M107, the Company’s novel small molecule drug candidate being advanced as a potential disease modifying treatment for gastroparesis (i.e., stomach paralysis). The collaboration leverages the combined scientific and clinical expertise of both organizations to target macrophage related inflammation and seeks to address the biological cause of gastroparesis, a chronic and debilitating disease affecting stomach nerves and muscles resulting in stomach paralysis and delayed stomach emptying. “We are proud to announce this collaboration with Mayo Clinic to bring this potential new treatment to patients,” stated Raymond K. Houck, Chief Executive Officer of Aclipse Therapeutics. Houck continued “M107 is an orally available small molecule drug with anti-inflammatory benefits and a clinically favorable safety profile that has been shown to promote increased expression of M2 macrophages and decreased expression of M1 macrophages, thereby addressing macrophage dysregulation and highlighting its disease-modifying potential in gastroparesis.” The M107 Phase 2 study, Lobeglitazone for the treatment of idiopathic gastroparesis (the LOGAST trial), is to be conducted under the direction of Principal Investigator Dr. Pankaj Jay Pasricha, MBSS, MD, Chair, Department of Internal Medicine, Mayo Clinic Arizona. The LOGAST trial, expected to begin enrollment during the first quarter of 2026, is slated to involve approximately 10 clinical investigators at three Mayo clinical and research campuses: Rochester, MN, Phoenix, AZ, and Jacksonville, FL. The study is an investigator initiated clinical trial sponsored by Mayo Clinic and supported through a research grant from Aclipse Therapeutics. Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research. About Aclipse Therapeutics Aclipse Therapeutics develops novel and highly differentiated immunological and anti-inflammatory therapeutics to treat life-threatening and severe diseases. Aclipse focuses on molecular pathways that regulate cellular stress, protein misfolding and inflammation in neuromuscular diseases that are strongly impacted by these molecular pathways. In addition to our M107 program, we are initiating a Phase 1 trial of M102, our NRF2 and HSF1 motor neuron protectant for the treatment of ALS (also known as Lou Gerhig’s or Motor Neuron Disease) in collaboration with the Sheffield Institute for Translational Neuroscience at the University of Sheffield, UK. For more information about Aclipse Therapeutics, visit the website at https://www.aclipsetherapeutics.com or email info@aclipsetherapeutics.com.

Phase 2Phase 1

05 Jan 2024

·synapse.patsnap.com

Demystifying PPAR agonists: A Comprehensive Guide and How to Keep Up with the Latest Developments

PPAR, or peroxisome proliferator-activated receptor, is a group of nuclear receptor proteins found in the human body. These receptors play a crucial role in regulating various physiological processes, including metabolism, inflammation, and cell differentiation. PPARs act as transcription factors, meaning they can influence gene expression by binding to specific DNA sequences. They are involved in lipid and glucose metabolism, making them important targets for pharmaceutical interventions in conditions like diabetes, obesity, and cardiovascular diseases. PPARs also have anti-inflammatory properties and are implicated in regulating immune responses. Understanding the role of PPARs is essential for developing drugs that can modulate these receptors and potentially treat various diseases. PPAR agonists play a crucial role in metabolic regulation and have significant medicinal properties. Many PPAR agonists have been synthesized for the treatment of metabolic diseases, particularly dyslipidemia and type 2 diabetes mellitus (T2DM). For instance, selective PPARα agonists like bezafibrate, in combination with statins, are used to treat atherosclerotic hyperlipidemia and hypertriglyceridemia. Thiazolidinediones (TZDs) are effective PPARγ activators used as insulin sensitizers to treat T2DM patients. Given the clear lipid-lowering activity of PPARα agonists and the insulin-sensitizing effect of PPARγ agonists, successful clinical studies of bezafibrate and TZDs have not only promoted the development of various PPARα/γ agonists but also triggered the formulation of novel PPAR modulators, including selective PPARβ/δ activators, dual PPAR agonists, and pan-PPAR agonists. Besides dyslipidemia and T2DM, PPAR has profound effects on other aspects of metabolic syndrome (MetS), such as diabetic complications, non-alcoholic fatty liver disease (NAFLD), and non-metabolic diseases including neurodegenerative diseases, cancer, and inflammatory diseases. Therefore, research on PPAR agonists in various diseases and complications has attracted widespread interest. The analysis of the target PPAR reveals a competitive landscape with multiple companies actively developing drugs. Takeda Pharmaceutical Co., Ltd., Viatris Inc., GSK Plc, CHEPLAPHARM Arzneimittel GmbH, and Pfizer Inc. are among the companies with the highest phase of development. The approved indications for target PPAR drugs primarily focus on hyperlipidemias and diabetes mellitus type 2. Small molecule drugs dominate the drug types being developed, indicating intense competition. China, the European Union, Japan, and the United States are leading in the development of target PPAR drugs. Overall, the target PPAR market shows promising growth potential, with a focus on lipid-related disorders and diabetes. How do they work?PPAR agonists are a class of drugs that activate peroxisome proliferator-activated receptors (PPARs) in the body. PPARs are a group of nuclear receptors that play a crucial role in regulating gene expression and controlling various metabolic processes. There are three subtypes of PPARs: PPAR-alpha, PPAR-gamma, and PPAR-delta. PPAR agonists bind to these receptors and modulate their activity, leading to specific physiological effects. PPAR-alpha agonists primarily target lipid metabolism and are used to treat dyslipidemia and reduce triglyceride levels. PPAR-gamma agonists mainly affect glucose metabolism and insulin sensitivity, making them useful in managing type 2 diabetes. PPAR-delta agonists are involved in regulating fatty acid oxidation and energy expenditure. By activating PPARs, these agonists can influence gene expression related to lipid metabolism, glucose homeostasis, inflammation, and other processes. This class of drugs has shown potential in treating metabolic disorders, such as dyslipidemia, insulin resistance, and obesity. However, it is important to note that the specific effects and applications of PPAR agonists can vary depending on the subtype targeted and the specific drug used. List of PPAR AgonistsThe currently marketed PPAR agonists include: Chiglitazar SodiumFenofibrate/Pitavastatin CalciumPemafibrateFenofibrate/SimvastatinLobeglitazone SulfateSaroglitazarPravastatin sodium/FenofibrateFenofibric acidCholine FenofibrateKetoprofen/OmeprazoleFor more information, please click on the image below. What are PPAR agonists used for?PPAR agonists are commonly used in managing type 2 diabetes. For more information, please click on the image below to log in and search. How to obtain the latest development progress of PPAR agonists?In the Synapse database, you can keep abreast of the latest research and development advances of PPAR agonists anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

14 Sep 2023

·www.biospace.com

Aclipse Therapeutics Expands Drug Development Pipeline with Signing of Exclusive, Worldwide License Agreement with Chong Kun Dang Pharmaceutical Corporation to Develop Potential Disease-Modifying Treatment for Gastroparesis

Company to advance M107 into Phase 2 clinical development in gastroparesis based on feedback from Pre-IND meeting with FDA RADNOR, Pa.--(BUSINESS WIRE)-- Aclipse Therapeutics, and its subsidiary, Aclipse Two, Inc (“Aclipse”), an innovative biopharmaceutical company developing life-changing treatments for patients with severe diseases, announced today that it has signed an exclusive license agreement with Seoul, South Korea-based Chong Kun Dang Pharmaceutical Corporation (“CKD”) for the worldwide rights (excluding South Korea, Indonesia and Vietnam) to develop CKD’s lobeglitazone for gastroparesis and additional indications. Gastroparesis is the delayed gastric emptying of food in the absence of mechanical obstruction, a condition which affects an estimated 600,000 patients in the U.S. and is increasing due to the increased use of GLP-1 drugs for diabetes and obesity. Lobeglitazone, given the development code “M107” by Aclipse, was developed by CKD and approved by South Korea’s Ministry of Food and Drug Safety for the treatment of Type 2 Diabetes Mellitus under the brand name, Duvie®. Lobeglitazone has shown an extensive history of safety, having been dosed in over 3,600 patients and healthy volunteers during its development and post-marketing surveillance. M107 is an oral, small molecule New Chemical Entity (“NCE”) in the U.S., EU, Japan, and China. With the support of CKD, Aclipse has conducted a successful pre-investigational new drug (Pre-IND) meeting with the U.S. Food and Drug Administration (“FDA”) to align FDA’s view of M107’s existing safety data and Aclipse’s Phase 2 and Phase 3 development plans in gastroparesis. “The worldwide, exclusive license agreement with CKD expands the Aclipse drug development pipeline and advances the company into Phase 2 clinical development for this promising drug candidate,” said Raymond K. Houck, Chief Executive Officer of Aclipse. “Our collaboration with CKD has been highly productive, allowing us to successfully conduct our pre-IND meeting with FDA and position M107, potentially, as the first disease-modifying treatment for gastroparesis.” “The license agreement with Aclipse represents an important milestone for lobeglitazone, as it will help to build upon the already extensive safety, efficacy and post-marketing data generated, to date, and provides the opportunity to extend lobeglitazone’s use to additional, key disease indications, worldwide,” said Young-Joo Kim, Chief Executive Officer of Chong Kun Dang Pharmaceutical Corporation. “We look forward to continuing our partnership with Aclipse and to the further clinical and commercial development of lobeglitazone.” About Gastroparesis Gastroparesis is the delayed gastric emptying of food in the absence of mechanical obstruction. It is a severe chronic disease that affects an estimated 600,000 patients in the U.S. with those patients having a high hospitalization rate1. Over half of gastroparesis patients exhibit severe or very severe disease and two-thirds of patients report being dissatisfied with current treatments2. Current FDA approved and in-development drugs only treat symptoms of the disease. About Aclipse Therapeutics Aclipse Therapeutics is an innovative biopharmaceutical company developing life-changing treatments for patients with severe diseases. The company’s current pipeline includes M107, a potential disease-modifying drug for the treatment of gastroparesis proceeding to Phase 2 development, and M102, a dual Nrf2/HSF1 activator for the treatment of ALS and other neurodegenerative diseases proceeding to Phase 1 development. M102 uses a precision medicine approach to identify those ALS patients who are most likely to benefit from the drug. Aclipse has an experienced drug development team and clinical advisory boards of key opinion leaders in gastroparesis and ALS. For more information about Aclipse Therapeutics, visit the website at or email info@aclipsetherapeutics.com. About Chong Kun Dang Pharmaceutical Corporation Chong Kun Dang Pharmaceutical Corporation (“CKD”) is a South Korea-based, fully integrated pharmaceutical company established in 1941. The company has the capacity to research and develop pharmaceutical products in oncology, neurology, immunology, metabolic disease, and other diseases. Its product portfolio includes prescription products in multiple therapeutic classes as well as consumer products. The company’s Chong Kun Dang Research Institute has three independent laboratories: The New Drug Discovery Labs; The Technology Development Labs; and the Bio Research Labs. CKD's R&D Investment and efforts are accelerating the development of new drugs, and these efforts are expanding the pipeline for the focused disease areas. Also, CKD manufactures, distributes, imports and exports prescription drugs, OTC drugs, health supplements and consumer health products. The company has manufacturing facilities in Cheonan City, South Korea and is headquartered in Seoul, South Korea. References: Wadhwa et al., 2017 W J Gastroenterol 23(24) 4428-4436 Yu at el., 2017 Dig Dis Sci 62, 879-893

License out/inDrug ApprovalPhase 2

100 Deals associated with Lobeglitazone Sulfate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Lobeglitazone Sulfate	A10B	DB09198

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	South Korea	Chong Kun Dang Pharmaceutical Corp.	04 Jul 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


REFIND (Pubmed \| Diabetes Obes Metab) Manual	Phase 4	Diabetes Mellitus, Type 2	147	lobeglitazone (low-dose)	idhmcfalzv(snlqvsdnyy) = nmolsymxur kcjmyigpjq (cegyimwfxb, 0.54) View more	Positive	17 May 2022
				lobeglitazone (standard-dose)	idhmcfalzv(snlqvsdnyy) = lshihtutvp kcjmyigpjq (cegyimwfxb, 0.46) View more
NCT01106131 (Pubmed \| Diabetes Ther)	Phase 3	Diabetes Mellitus, Type 2	253	Lobeglitazone	esmlhrtett(wvutegaqbf) = vlrihfrgfk tnbvkhopby (qlymwibbtu ) View more	-	01 Jan 2021
				Pioglitazone	vmcdrsmeos(ochozdeprm) = nntywbkcnn kvtkcimntc (vagnmrngox ) View more
NCT02480465 (Pubmed) Manual	Phase 4	Metabolic Syndrome \| Diabetes Mellitus, Type 2	247	lobeglitazone	zkzsuofftk(mpzrbkhwvq) = xfcowsfusv ihbhkftjzw (scawelyzbl )	Positive	01 Oct 2020
				sitagliptin	zkzsuofftk(mpzrbkhwvq) = ntylhbliol ihbhkftjzw (scawelyzbl )
NCT02480465 (EASD2019)	Phase 4	Metabolic Syndrome \| Diabetes Mellitus, Type 2 Add-on	247	Lobeglitazone 0.5 mg	dwfqdcbrai(voayvtybum) = demonstrating non-inferiority ehcltnpcvr (hsbwdglljn ) View more	Positive	17 Sep 2019
				Sitagliptin 100 mg
NCT01106131 (Pubmed \| Diabetes Obes Metab) Manual	Phase 3	Diabetes Mellitus, Type 2	253	Lobeglitazone	bbqdpoqxaw(kcpnrhlhxl) = amvvwvgrlt rjuksnmdxf (oyhoyappwz )	Non-inferior	01 Jun 2015
				pioglitazone	bbqdpoqxaw(kcpnrhlhxl) = hifbaflxcz rjuksnmdxf (oyhoyappwz )
NCT01330563 (Pubmed \| Clin Ther)	Phase 1	Diabetes Mellitus, Type 2	24	Lobeglitazone 0.5 mg	vbophasqct(goptjxwwpb) = rwhuepwmsg axepqlauro (jmqztshjrd ) View more	-	01 Jul 2014
				Lobeglitazone 0.5 mg + Ketoconazole	vbophasqct(goptjxwwpb) = hsratkgblu axepqlauro (jmqztshjrd ) View more
NCT01001611 (Pubmed \| PLoS One)	Phase 3	Diabetes Mellitus, Type 2	173	Lobeglitazone 0.5 mg	xldjpifnlk(ukqzovrgyr) = uzvmdwdlyv bdqkgbhsqr (eggvnlcemc ) View more	Positive	01 Jan 2014
				Placebo	xldjpifnlk(ukqzovrgyr) = cazwmbchtd bdqkgbhsqr (eggvnlcemc ) View more
NCT01001611 (EASD2013)	Phase 3	Diabetes Mellitus, Type 2	173	Lobeglitazone 0.5 mg (Group M)	sdtbzecoaz(hxhyfizmlc) = ymnnxniexy xekfsgkvzi (gcvsifoafc ) View more	Positive	25 Sep 2013
				Lobeglitazone 0.5 mg (Group S)	sdtbzecoaz(hxhyfizmlc) = gmgeipdaec xekfsgkvzi (gcvsifoafc ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis